Literature DB >> 6393863

Suppression of respiratory syncytial virus infection in cotton rats by bis(5-amidino-2-benzimidazolyl)methane.

R R Tidwell, J D Geratz, W A Clyde, K U Rosenthal, E J Dubovi.   

Abstract

Intraperitoneal administration of bis(5-amidino-2-benzimidazolyl)methane at well-tolerated daily doses of 25 mg/kg subsequent to challenge and for 3 days thereafter effected over a 1-log reduction in the amount of virus recovered from lungs of cotton rats inoculated intratracheally with respiratory syncytial virus. When animals were immunosuppressed to prolong virus shedding, the reduction in recovered virus achieved with a 7-day dosing schedule of bis(5-amidino-2-benzimidazolyl)methane exceeded 2 logs.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6393863      PMCID: PMC179971          DOI: 10.1128/AAC.26.4.591

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies.

Authors:  E E Walsh; J J Schlesinger; M W Brandriss
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

2.  Inhibition of respiratory syncytial virus by bis(5-amidino-2-benzimidazolyl)methane.

Authors:  E J Dubovi; J D Geratz; R R Tidwell
Journal:  Virology       Date:  1980-06       Impact factor: 3.616

3.  Inhibition of respiratory syncytial virus-host cell interactions by mono- and diamidines.

Authors:  E J Dubovi; J D Geratz; S R Shaver; R R Tidwell
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

4.  In vivo inhibition of respiratory syncytial virus by ribavirin.

Authors:  J F Hruska; P E Morrow; S C Suffin; R G Douglas
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

5.  Respiratory syncytial virus infection in cyclophosphamide-treated cotton rats.

Authors:  R A Johnson; G A Prince; S C Suffin; R L Horswood; R M Chanock
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

6.  Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice.

Authors:  S Z Wilson; V Knight; P R Wyde; S Drake; R B Couch
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

7.  Effects of ribavirin on respiratory syncytial virus in vitro.

Authors:  J F Hruska; J M Bernstein; R G Douglas; C B Hall
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

8.  Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants.

Authors:  L H Taber; V Knight; B E Gilbert; H W McClung; S Z Wilson; H J Norton; J M Thurson; W H Gordon; R L Atmar; W R Schlaudt
Journal:  Pediatrics       Date:  1983-11       Impact factor: 7.124

9.  Enhancement of respiratory syncytial virus-induced cytopathology by trypsin, thrombin, and plasmin.

Authors:  E J Dubovi; J D Geratz; R R Tidwell
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

10.  The cotton rat as an experimental model of human parainfluenza virus type 3 disease.

Authors:  T F Murphy; E J Dubovi; W A Clyde
Journal:  Exp Lung Res       Date:  1981-05       Impact factor: 2.459

View more
  8 in total

1.  In vitro inhibition of human sarcoma cells' invasive ability by bis(5-amidino-2-benzimidazolyl)methane--a novel esteroprotease inhibitor.

Authors:  D H Cresson; W C Beckman; R R Tidwell; J D Geratz; G P Siegal
Journal:  Am J Pathol       Date:  1986-04       Impact factor: 4.307

2.  Highly active anti-Pneumocystis carinii compounds in a library of novel piperazine-linked bisbenzamidines and related compounds.

Authors:  Melanie T Cushion; Peter D Walzer; Margaret S Collins; Sandra Rebholz; Jean Jacques Vanden Eynde; Annie Mayence; Tien L Huang
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

3.  Anti-Pneumocystis activities of aromatic diamidoxime prodrugs.

Authors:  J E Hall; J E Kerrigan; K Ramachandran; B C Bender; J P Stanko; S K Jones; D A Patrick; R R Tidwell
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

4.  Protease inhibitors suppress the in vitro and in vivo replication of rotavirus.

Authors:  S L Vonderfecht; R L Miskuff; S B Wee; S Sato; R R Tidwell; J D Geratz; R H Yolken
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

5.  Inhibitory effects of antiviral compounds on respiratory syncytial virus replication in vitro.

Authors:  F Kawana; S Shigeta; M Hosoya; H Suzuki; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

6.  Sequential events in the pathogenesis of streptococcal cell wall-induced arthritis and their modulation by bis(5-amidino-2-benzimidazolyl)methane (BABIM).

Authors:  J D Geratz; R R Tidwell; J H Schwab; S K Anderle; K B Pryzwansky
Journal:  Am J Pathol       Date:  1990-04       Impact factor: 4.307

7.  Orally active fusion inhibitor of respiratory syncytial virus.

Authors:  Christopher Cianci; Kuo-Long Yu; Keith Combrink; Ny Sin; Bradley Pearce; Alan Wang; Rita Civiello; Stacey Voss; Guangxiang Luo; Kathy Kadow; Eugene V Genovesi; Brian Venables; Hatice Gulgeze; Ashok Trehan; Jennifer James; Lucinda Lamb; Ivette Medina; Julia Roach; Zheng Yang; Lisa Zadjura; Richard Colonno; Junius Clark; Nicholas Meanwell; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

8.  Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection.

Authors:  Christopher Cianci; Eugene V Genovesi; Lucinda Lamb; Ivette Medina; Zheng Yang; Lisa Zadjura; Hyekyung Yang; Celia D'Arienzo; Ny Sin; Kuo-Long Yu; Keith Combrink; Zhufang Li; Richard Colonno; Nicholas Meanwell; Junius Clark; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.